TB-500 5MG
Buy 3 for $45.89 each and save 10%
Buy 5 for $40.79 each and save 20%
Buy 10 for $35.69 each and save 30%
Buy this product and Earn 51.00 Reward Points click here to login
FREE Shipping for orders over $200
For this product you will need: BACTERIOSTATIC WATER For reconstitution.
Sarms
Stacks
Research Liquids
Albuterol 5MG/ML | 30ML with dropper
Anastrozole 1.5MG/ML | 30ML with dropper
Clomiphene 50MG/ML | 30ML with dropper
Finasteride 5MG/ML | 30ML with dropper
Letrozole 3.5 MG/ML | 30ML with dropper
LiquiCia 30MG/ML | 30ML with dropper
LiquiCia T50 50MG/ML | 30ML with dropper
LiquiClen 200MCG/ML | 30ML with dropper
Liquistane / Exemestane 25MG/ML | 30ML with dropper
LiquiTamo 20MG/ML | 30ML with dropper
LiquiVia 25MG/ML | 30 ML with dropper
T3 LIOTHYRONINE 200MCG/ML | 30ML with dropper
Toremifene Citrate 60MG/ML | 30ML with dropper
Yohimbine HCL 10MG/ML | 30ML with dropper
Research Peptides
Aicar 50MG
BPC-157 + TB-500 Blend 2mg ea/ 4MG
BPC-157 5MG
CJC-1295 + DAC 2MG
CJC-1295 | No DAC 2MG
Epithalon 10MG
Frag Premium 176-191 5MG
GHK-CU Copper Peptide 50MG
GHRP-2 5MG
GHRP-6 5MG
Hexarelin 5MG
IGF-1 DES 1MG
IGF-1 LR3 1MG
Ipamorelin 5MG
Melanotan 2 10MG
NAD+ 500MG
PT-141 / Bremelanotide 10MG
GLP-1/GIP/GCG (RT)
Selank 5MG
GLP1 (SM)
Sermorelin 5MG
TB-500 5MG
Tesamorelin
GIP/GLP-1 (TZ)
PDE5 Inhibitors
GLP-1
Diluents
Bacteriostatic Water 10ML
What Is TB-500 5MG?
Tb-500 is a man-made analogue of thymosin beta-4, a naturally occurring peptide produced by the thymus gland. Thymosin beta-4 is involved in the mediation of various biological processes, including cell differentiation, angiogenesis, tissue regeneration, wound healing and many other functions. It is made up of 43 amino acids and is present in different cells of the body including saliva, tears, wound fluid and blood. Most of the research points to the use of thymosin beta-4, a structurally similar compound to the TB-500, so synthetic TB-500 is expected to replicate similar results as Tβ4 [1].
Thymosin beta 4 was first isolated from the bovine thymus gland in the 1980s. After that, its synthetic version TB-500 was developed in 2010. Although being developed for veterinary purposes, people started using it in competitive horse racing, purposefully offering a distinct edge to treated horses. Consequently, its use got banned in horse racing and sports competitions. On our website, Tb-500 for sale is limited to educational and research purposes.
Structure Of TB-500 5MG
From Pubchem
Synonyms: QHK6Z47GTG, TB-500Molecular Formula: C38H68N10O14Molecular Weight: 889.0 g/molSequence: LKKTETQCAD Number: 885340-08-9PubChem CID: 62707662
TB-500 5MG Uses In Research
1. TB-500 and Angiogenesis
TB-500 is known to be involved in the formation of new blood vessels; a process known as neovascularization. One research identifies Tβ4 as essential for the development of coronary vessels in mice. Further, the experiment reveals that the test compound triggers the growth of previously inactive epicardial explants and the differentiation of fibroblasts, muscle cells and endothelial cells [2].
A study was conducted to assess the mechanism behind the angiogenic effect of Tβ4. The test tubes containing endothelial cells were treated with Tβ4, along with inhibition of AKT and PI3Kα/Rho pathway. Further, in vivo studies using animal models (mice and rabbit) were done by injecting Tβ4 either along with the application of rAAV.AKT-dn or inhibition of Rho/PI3K/AKT pathways. Kindly note that AKT is a kinase protein crucial for the PI3/AKT pathway, and AKT-dn is a negative dominant form of AKT that disturbs its normal function. The results of this study found reduced formation of blood vessels with the inhibition of the PI3/AKT pathway, indicating its importance in mediating angiogenesis [3].
2. TB-500 and Muscular Dystrophy:
In a study, dystrophin-deficient mice, the mouse model of Duchenne muscular dystrophy, was treated with Tβ4 twice a week for six months. Results found an increased number of muscle-regenerating fibers in mice treated with Tβ4 as compared to untreated ones, indicating the potential of Tb-4 as an effective therapy for muscular dystrophy [4]. Furthermore, thymosin beta-4 promotes the survival of cardiomyocytes and repairs damage to the heart [5].
3. Tb-500 and Recovery from Injury:
Various studies on animal models found that thymosin beta-4 can aid in wound healing and speed up recovery from injuries. One study in rats found Tb-4 to be effective in treating incisional wounds with minimal scarring. Moreover, it revealed that wounds treated with the peptide were narrow in width, had more organized collagen fibers and displayed red birefringence (an indication of mature connective tissues). While the untreated wounds displayed green birefringence, indicative of immature connective tissues, and had disorganized collagen fibers [6].
In a study, Tβ4 treatment six hours after traumatic brain injury lessened the size of cortical lesions and improved functional recovery in rats. While delayed treatment (24 hours after injury) didn’t alter the size of cortical lesions but significantly affected functional recovery in rats [7].
In a randomized double-blind, placebo-controlled, dose-escalation phase II trial, topical administration of Tβ4 improved wound healing in patients with venous ulcers. Furthermore, it found that a 0.03% dose of synthetic thymosin beta-4 helped 25% of the patients achieve full recovery whose wound size was small to moderate [8].
Thymosin beta 4 is believed to improve the recovery of injured tissues through its actin-sequestering properties. In the site of injury, thymosin B-4 binds with actin that promotes migration and differentiation of stem cells, resulting in the formation of new vessels that aid in wound healing. Further, it causes decreases in the number of myofibroblasts at the site of injury, thus reducing scar formation [9].
4. Thymosin Beta 4 and Dry Eyes.
Thymosin beta-4 might be involved in the healing of the corneal surface. A study conducted on 72 subjects found 0.1% Tβ4 as an effective treatment for relieving symptoms of dry eyes with no adverse effects being reported [10].
In another study, nine patients with severe dry eyes were given Tβ4 eye drops or placebo six times per day for 28 days. Participants treated with the drug experienced a 35.3% reduction of ocular discomfort, 59.1% reduction of total corneal fluorescein staining and increased tear production as compared to those who received a placebo [11].
5. Current status of Tb-500
Various studies on animal models speak for the beneficial effect of Tb-4 in wound healing and angiogenesis. It hasn't been yet approved by the FDA for clinical use in humans. More research is needed to confirm the medicinal effects of TB-500 in humans. As an experimental drug, TB-500 purchase is limited for research, only buy Tb-500 if you are a licensed researcher.
Referenced Citations
Ho, E.N.M., et al., Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography–mass spectrometry. Journal of Chromatography A, 2012. 1265: p. 57-69.
Smart, N., et al., Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature, 2007. 445(7124): p. 177-82.
Trenkwalder, T., et al., Thymosin-β4-mediated therapeutic neovascularization: role of the PI3K/AKT pathway. Expert Opin Biol Ther, 2015. 15 Suppl 1: p. S175-85.
Spurney, C.F., et al., Evaluation of skeletal and cardiac muscle function after chronic administration of thymosin beta-4 in the dystrophin deficient mouse. PLoS One, 2010. 5(1): p. e8976.
Bjørklund, G., M. Dadar, J. Aaseth, and S. Chirumbolo, Thymosin β4: A Multi-Faceted Tissue Repair Stimulating Protein in Heart Injury. Curr Med Chem, 2020. 27(37): p. 6294-6305.
Ehrlich, H.P. and S.W. Hazard, 3rd, Thymosin beta4 enhances repair by organizing connective tissue and preventing the appearance of myofibroblasts. Ann N Y Acad Sci, 2010. 1194: p. 118-24.
Xiong, Y., et al., Neuroprotective and neurorestorative effects of thymosin β4 treatment following experimental traumatic brain injury. Ann N Y Acad Sci, 2012. 1270: p. 51-8.
Guarnera, G., A. DeRosa, and R. Camerini, The effect of thymosin treatment of venous ulcers. Ann N Y Acad Sci, 2010. 1194: p. 207-12.
Goldstein, A.L., E. Hannappel, G. Sosne, and H.K. Kleinman, Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther, 2012. 12(1): p. 37-51.
Sosne, G., et al., Thymosin Beta 4 Eye Drops Significantly Improve Signs and Symptoms of Severe Dry Eye in a Physician-Sponsored Phase 2 Clinical Trial. Investigative Ophthalmology & Visual Science, 2013. 54(15): p. 6033-6033.
Sosne, G. and G.W. Ousler, Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAETM) model. Clin Ophthalmol, 2015. 9: p. 877-84.
Certificate of Analysis (COA)
High Performance Liquid Chromatography (HPLC)
Mass Spectrometry (MS)
TB-500 5MG — Research Grade
C212H350N56O78S
4963.5 g/mol
77591-33-4
ES-TB-5
TB-500 is a synthetic analogue of Thymosin Beta-4, derived from the actin-binding domain and retaining the core tetrapeptide sequence (LKKTETQ) associated with documented biochemical activity in research models.
In cell-based and biochemical research, TB-500 is used in assays examining actin polymerisation dynamics, G-actin sequestration, and cell migration behaviour. Published studies have characterised its interactions with anti-inflammatory cytokine signalling pathways and extracellular matrix protein expression in cell culture models.
Element SARMs supplies TB-500 at 5mg per vial. USA-manufactured via solid-phase synthesis and verified at 99%+ purity by HPLC and Mass Spectrometry. Reconstitution with bacteriostatic water required. Store lyophilised at -20C; stable 24 months.
WARNING: For research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any disease. For use by qualified research professionals only.
Submit your review to Earn 50 Reward Points click here to login